Signaling by death receptors in the nervous system

Current Opinion in Neurobiology

Volumn 18, Issue 3, 2008, Pages 284-291

  Haase, Georg ^a   Pettmann, Brigitte ^b   Raoul, Cédric ^b   Henderson, Christopher E ^c  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b Turing Center for Living Systems CENTURI Aix Marseille University   (France)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; FAS LIGAND; FOLIC ACID; NEUROTROPHIN RECEPTOR P75; SOMATOMEDIN C; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

AMYOTROPHIC LATERAL SCLEROSIS; CELL DEATH; CELL GROWTH; CELL SURVIVAL; DEGENERATION; HUMAN; NERVOUS SYSTEM; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; NERVOUS SYSTEM PHYSIOLOGICAL PHENOMENA; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION;

EID: 53949108541     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conb.2008.07.013     Document Type: Review

References (56)

1. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2 (2002) 420-430
2. Peter M.E., Budd R.C., Desbarats J., Hedrick S.M., Hueber A.O., Newell M.K., Owen L.B., Pope R.M., Tschopp J., Wajant H., et al. The CD95 receptor: apoptosis revisited. Cell 129 (2007) 447-450. This collaborative review summarizes well the changes in thinking in the field about the relative weight to be given to the pro- and anti-apoptotic functions of death receptors. It focuses on the prototypic death receptor Fas/CD95, but many of its conclusions are undoubtedly relevant for other family members.
3. Beier C.P., Wischhusen J., Gleichmann M., Gerhardt E., Pekanovic A., Krueger A., Taylor V., Suter U., Krammer P.H., Endres M., et al. FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. J Neurosci 25 (2005) 6765-6774
4. + efflux in neuronal cell death.
5. Fernandez M., Segura M.F., Sole C., Colino A., Comella J.X., and Cena V. Lifeguard/neuronal membrane protein 35 regulates Fas ligand-mediated apoptosis in neurons via microdomain recruitment. J Neurochem 103 (2007) 190-203
6. Jurewicz A., Matysiak M., Andrzejak S., and Selmaj K. TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway. Glia 53 (2006) 158-166
7. Murata T., Tsuboi M., Hikita K., and Kaneda N. Protective effects of neurotrophic factors on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of murine adrenal chromaffin cell line tsAM5D. J Biol Chem 281 (2006) 22503-22516
8. Pehar M., Vargas M.R., Robinson K.M., Cassina P., Diaz-Amarilla P.J., Hagen T.M., Radi R., Barbeito L., and Beckman J.S. Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. J Neurosci 27 (2007) 7777-7785
9. Raoul C., Barthelemy C., Couzinet A., Hancock D., Pettmann B., and Hueber A.O. Expression of a dominant negative form of Daxx in vivo rescues motoneurons from Fas (CD95)-induced cell death. J Neurobiol 62 (2005) 178-188
10. Raoul C., Buhler E., Sadeghi C., Jacquier A., Aebischer P., Pettmann B., Henderson C.E., and Haase G. Chronic activation in presymptomatic amyotrophic lateral sclerosis (ALS) mice of a feedback loop involving Fas, Daxx, and FasL. Proc Natl Acad Sci U S A 103 (2006) 6007-6012. The article demonstrates the existence of a feedback loop through which nitric oxide, a product of Fas activation in motor neurons, leads to upregulation of FasL and therefore further activation of the Fas pathway. Evidence for early activation of several intermediates in this feedback loop has been found in presymptomatic ALS model mice. It is tempting to speculate that low-level activation of such processes leads to a build-up of toxic intermediates that is only gradual, and which could therefore explain the late onset of ALS in patients and animal models.
11. L as an endogenous modulator of death receptor signaling in neurons.
12. Sotthibundhu A., Sykes A.M., Fox B., Underwood C.K., Thangnipon W., and Coulson E.J. Beta-amyloid(1-42) induces neuronal death through the p75 neurotrophin receptor. J Neurosci 28 (2008) 3941-3946
13. Swarup V., Das S., Ghosh S., and Basu A. Tumor necrosis factor receptor-1-induced neuronal death by TRADD contributes to the pathogenesis of Japanese encephalitis. J Neurochem 103 (2007) 771-783
14. Underwood C.K., Reid K., May L.M., Bartlett P.F., and Coulson E.J. Palmitoylation of the C-terminal fragment of p75(NTR) regulates death signaling and is required for subsequent cleavage by gamma-secretase. Mol Cell Neurosci 37 (2008) 346-358
15. Wetzel M., Li L., Harms K.M., Roitbak T., Ventura P.B., Rosenberg G.A., Khokha R., and Cunningham L.A. Tissue inhibitor of metalloproteinases-3 facilitates Fas-mediated neuronal cell death following mild ischemia. Cell Death Differ 15 (2008) 143-151
16. Ugolini G., Raoul C., Ferri A., Haenggeli C., Yamamoto Y., Salaun D., Henderson C.E., Kato A.C., Pettmann B., and Hueber A.O. Fas/tumor necrosis factor receptor death signaling is required for axotomy-induced death of motoneurons in vivo. J Neurosci 23 (2003) 8526-8531
17. Zuliani C., Kleber S., Klussmann S., Wenger T., Kenzelmann M., Schreglmann N., Martinez A., del Rio J.A., Soriano E., Vodrazka P., et al. Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death Differ 13 (2006) 31-40. This is one of the only few studies to provide clear in vivo loss-of-function data for non-apoptotic roles for death receptors, in this case Fas/CD95. The results point to a role for Fas in axonal and dendritic branching and provide an intriguing potential explanation for the behavioral deficits observed in animals and patients with mutations in the fas/cd95 gene.
18. Kaneko M., Stellwagen D., Malenka R.C., and Stryker M.P. Tumor necrosis factor-alpha mediates one component of competitive, experience-dependent plasticity in developing visual cortex. Neuron 58 (2008) 673-680
19. Stellwagen D., and Malenka R.C. Synaptic scaling mediated by glial TNF-alpha. Nature 440 (2006) 1054-1059
20. •].
21. •].
22. •].
23. Hensley K., Mhatre M., Mou S., Pye Q.N., Stewart C., West M., and Williamson K.S. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal 8 (2006) 2075-2087
24. Veglianese P., Lo Coco D., Bao Cutrona M., Magnoni R., Pennacchini D., Pozzi B., Gowing G., Julien J.P., Tortarolo M., and Bendotti C. Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Mol Cell Neurosci 31 (2006) 218-231
25. Cereda C., Baiocchi C., Bongioanni P., Cova E., Guareschi S., Metelli M.R., Rossi B., Sbalsi I., Cuccia M.C., and Ceroni M. TNF and sTNFR1/2 plasma levels in ALS patients. J Neuroimmunol 194 (2008) 123-131
26. Gowing G., Dequen F., Soucy G., and Julien J.P. Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J Neurosci 26 (2006) 11397-11402. Although the results could be classified as negative, this study provides a clear demonstration of the power of mouse genetics in vivo to support (or in this case weaken) hypotheses developed in vitro. In the present case, the absence of TNFα does not affect the ALS-like disease process in SOD1 mice, arguing against a role for TNFα either as a death inducer for motor neurons or as a mediator of gliosis.
27. Bigini P., Repici M., Cantarella G., Fumagalli E., Barbera S., Cagnotto A., De Luigi A., Tonelli R., Bernardini R., Borsello T., et al. Recombinant human TNF-binding protein-1 (rhTBP-1) treatment delays both symptoms progression and motor neuron loss in the wobbler mouse. Neurobiol Dis 29 (2008) 465-476
28. Dodge J.C., Haidet A.M., Yang W., Passini M.A., Hester M., Clarke J., Roskelley E.M., Treleaven C.M., Rizo L., Martin H., et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of Aberrant Glial cell activity. Mol Ther 16 (2008) 1056-1064
29. Kiaei M., Petri S., Kipiani K., Gardian G., Choi D.K., Chen J., Calingasan N.Y., Schafer P., Muller G.W., Stewart C., et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 26 (2006) 2467-2473. The authors show that thalidomide and its analog lenalidomide are both capable of inhibiting the expression of TNFα and FasL in motor neurons of SOD1 mutant mice. These compounds also confer quite significant benefit in terms of lifespan of the ALS mice. It remains to be determined whether these two observations are linked, or whether thalidomide is acting through independent mechanisms to promote survival.
30. Petri S., Calingasan N.Y., Alsaied O.A., Wille E., Kiaei M., Friedman J.E., Baranova O., Chavez J.C., and Beal M.F. The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 102 (2007) 991-1000
31. Zhang X., Chen S., Li L., Wang Q., and Le W. Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1 G93A transgenic mice. Neuropharmacology 54 (2008) 1112-1119
32. Stommel E.W., van Hoff R.M., Graber D.J., Bercury K.K., Langford G.M., and Harris B.T. Tumor necrosis factor-alpha induces changes in mitochondrial cellular distribution in motor neurons. Neuroscience 146 (2007) 1013-1019
33. •] are significant because they clearly demonstrate the concept of active killing of motor neurons by glia in the mutant SOD1 mouse model of familial ALS.
34. Domeniconi M., Hempstead B.L., and Chao M.V. Pro-NGF secreted by astrocytes promotes motor neuron cell death. Mol Cell Neurosci 34 (2007) 271-279
35. Raoul C., Estevez A.G., Nishimune H., Cleveland D.W., deLapeyriere O., Henderson C.E., Haase G., and Pettmann B. Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron 35 (2002) 1067-1083
36. Locatelli F., Corti S., Papadimitriou D., Fortunato F., Del Bo R., Donadoni C., Nizzardo M., Nardini M., Salani S., Ghezzi S., et al. Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice. Ann Neurol 62 (2007) 81-92. The authors use intrathecal micropumps to administer siRNA to Fas to mutant SOD1 mice. They observe not only a complete return of the Fas/NO pathway to normal activation levels but also significant neuroprotection of motor neurons and prolongation of lifespan. The effects are particularly striking given that Fas siRNA was only administered for a limited time. These results are currently the strongest evidence for a role of Fas signaling in disease onset and progression in ALS. They will need to be confirmed using similar approaches in other ALS models, and by the use of mouse genetics to fully evaluate the protective effect of Fas/FasL depletion.
37. Kiaei M., Kipiani K., Calingasan N.Y., Wille E., Chen J., Heissig B., Rafii S., Lorenzl S., and Beal M.F. Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 205 (2007) 74-81
38. Lee J.K., Shin J.H., Suh J., Choi I.S., Ryu K.S., and Gwag B.J. Tissue inhibitor of metalloproteinases-3 (TIMP-3) expression is increased during serum deprivation-induced neuronal apoptosis in vitro and in the G93A mouse model of amyotrophic lateral sclerosis: a potential modulator of Fas-mediated apoptosis. Neurobiol Dis 30 (2008) 174-185
39. Shin J.H., Cho S.I., Lim H.R., Lee J.K., Lee Y.A., Noh J.S., Joo I.S., Kim K.W., and Gwag B.J. Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis. Mol Pharmacol 71 (2007) 965-975. This paper provides two types of evidence for a role for Fas receptor in neurodegeneration in ALS model mice. First, the authors show increased expression in SOD mice of Fas and its downstream signaling intermediates, and report that Fas-FADD interactions are intensified at one stage of the disease. In addition, they report that lithium can prevent neurodegeneration and lead to modest increases in lifespan of SOD1 mice. Lithium also strongly inhibits the expression of Fas and FADD, though it still needs to be determined whether this underlies its neuroprotective activity.
40. Petri S., Kiaei M., Wille E., Calingasan N.Y., and Flint Beal M. Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice. J Neurol Sci 251 (2006) 44-49
41. •].
42. Lorenzl S., Narr S., Angele B., Krell H.W., Gregorio J., Kiaei M., Pfister H.W., and Beal M.F. The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice. Exp Neurol 200 (2006) 166-171
43. Dewil M., Schurmans C., Starckx S., Opdenakker G., Van Den Bosch L., and Robberecht W. Role of matrix metalloproteinase-9 in a mouse model for amyotrophic lateral sclerosis. Neuroreport 16 (2005) 321-324
44. Yamamoto M., Kiyota T., Horiba M., Buescher J.L., Walsh S.M., Gendelman H.E., and Ikezu T. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 170 (2007) 680-692
45. Ackery A., Robins S., and Fehlings M.G. Inhibition of Fas-mediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury. J Neurotrauma 23 (2006) 604-616
46. Martin L.J., Chen K., and Liu Z. Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation. J Neurosci 25 (2005) 6449-6459
47. Taoufik E., Valable S., Muller G.J., Roberts M.L., Divoux D., Tinel A., Voulgari-Kokota A., Tseveleki V., Altruda F., Lassmann H., et al. FLIP(L) protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death. J Neurosci 27 (2007) 6633-6646
48. Luoma J.I., and Zirpel L. Deafferentation-induced activation of NFAT (nuclear factor of activated T-cells) in cochlear nucleus neurons during a developmental critical period: a role for NFATc4-dependent apoptosis in the CNS. J Neurosci 28 (2008) 3159-3169
49. Landau A.M., Luk K.C., Jones M.L., Siegrist-Johnstone R., Young Y.K., Kouassi E., Rymar V.V., Dagher A., Sadikot A.F., and Desbarats J. Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease. J Exp Med 202 (2005) 575-581
50. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., and O'Callaghan J.P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J 20 (2006) 670-682
51. Ruan W., Lee C.T., and Desbarats J. A novel juxtamembrane domain in TNF receptor superfamily molecules activates Rac1 and controls neurite growth. Mol Biol Cell 19 (2008) 3192-3202
52. Thornhill P.B., Cohn J.B., Drury G., Stanford W.L., Bernstein A., and Desbarats J. A proteomic screen reveals novel Fas ligand interacting proteins within nervous system Schwann cells. FEBS Lett 581 (2007) 4455-4462
53. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13 (2007) 1070-1077
54. Tsuruma K., Nakagawa T., Morimoto N., Minami M., Hara H., Uehara T., and Nomura Y. Glucocorticoid modulatory element-binding protein 1 binds to initiator procaspases and inhibits ischemia-induced apoptosis and neuronal injury. J Biol Chem 281 (2006) 11397-11404
55. Harry G.J., Lefebvre d'Hellencourt C., McPherson C.A., Funk J.A., Aoyama M., and Wine R.N. Tumor necrosis factor p55 and p75 receptors are involved in chemical-induced apoptosis of dentate granule neurons. J Neurochem 106 (2008) 281-298. This study investigates the role of TNF in neuronal damage induced by neuroinflammation. The toxin trimethyltin was known to induce a microglial response and an increase in TNFα, and is shown to induce cell death of hippocampal neurons. Genetic ablation of TNFR1 and/or TNFR2, or the use of antibodies to TNFα, both provide significant protection against the effects of toxin treatment.
56. Sriram K., Miller D.B., and O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem 96 (2006) 706-718